Call it a long, lucrative leash. In a deal announced today, NGM Biopharmaceuticals of South San Francisco, CA, has signed over 15 percent of its equity and potentially (Read more...)
Women’s health-focused biopharmaceutical researcher Evestra is taking a $5 million loan from existing partner Gedeon Richter so that it can further develop a product line that includes a (Read more...)
What’s the worst part of getting vaccinated? Most folks, outside of the anti-vaccination crowd, would probably say the needle prick. A startup named Vaxxas is one of (Read more...)
FDA Commissioner Margaret “Peggy” Hamburg will step down in March after nearly six eventful years, transforming the agency from one of the life science industry’s biggest bete noirs (Read more...)
These days, it seems biotech investors are happy to take all kinds of risk. But there are still times to hedge bets, which Atlas Venture did a few (Read more...)
The word “story” gets ill treatment at events like the J.P. Morgan Healthcare Conference. It often means an elevator pitch from a harried CEO to a distracted (Read more...)
The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it (Read more...)
Even a week after a $450 million round, the cash keeps flowing into Moderna Therapeutics.
The Cambridge, MA-based company announced this morning that Merck has become the latest (Read more...)
Anyone either celebrating or fearing the start of a Hepatitis C drug price war should take a break from the excitement to consider that a far more nuanced (Read more...)
The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and the healthcare system by (Read more...)
Tony Coles could easily be on a beach sipping mai tais right now. You can plan for an early retirement in biotech when you turn two different biotechs (Read more...)
Cubist Pharmaceuticals is one of biotech’s unlikely stories. Rising from a fortuitous licensing deal to become a leader in the antibiotics field, Lexington, MA-based Cubist made the big (Read more...)
When Ronald Renaud sold the company he was leading, Idenix Pharmaceuticals, to Merck for $3.85 billion six months ago, it was one of biotech’s more unexpected recent (Read more...)
It’s been a big year for Intarcia Therapeutics. The Boston- and Hayward, CA-based firm raised a massive round of private financing for its experimental drug/device combo treatment for (Read more...)
Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people ...